Xcout IntelCareDx, Inc.
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Subscribe to see CareDx, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CareDx, Inc. at a glance
CareDx, Inc. is a medical - diagnostics & research company headquartered in Brisbane, United States. It is publicly listed (CDNA) with a market capitalisation of $3.6B. Xcout tracks 25 named people at CareDx, Inc., including John Walter Hanna Jr. (President, Chief Executive Officer & Director). Xcout recorded 87 job postings from CareDx, Inc. in the last 90 days, naming tools such as Salesforce, Tableau, NetSuite.
CareDx, Inc. leadership
- John Walter Hanna Jr.President, Chief Executive Officer & Director
- John W. HannaPresident and Chief Executive Officer
- Keith S. KennedyCFO & COO
- Keith KennedyChief Financial Officer and Chief Operating Officer
- Kashif RathoreChief Technology Officer
- Jessica MengChief Commercial Officer
19 more named people on record for CareDx, Inc., with roles, board committees and tenure — see the full roster →
Hiring at CareDx, Inc.
Xcout recorded 87 job postings from CareDx, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in CareDx, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it and all 13 tools — see CareDx, Inc.'s hiring signals →
Recent CareDx, Inc. news
3 corporate events on record, with sources — see the full timeline →
Hiring vs the trend
Based on 45 job postings in the last 8 weeks (24 Aug – 18 Oct 2026), compared with 181 scale-up healthcare companies.
This describes a hiring pattern — how often CareDx, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
CareDx, Inc. competitors
A few of CareDx, Inc.'s closest competitors — see the full list of competitors and alternatives →
Orchestra Health Technologies provides a platform combining proprietary software and care navigators to streamline the oncology diagnostic journey from biopsy to treatment decisions. The company serves cancer patients, oncologists, pathologists, and healthcare executives by coordinating pathology, molecular testing, and multi-disciplinary team workflows to accelerate precision medicine.
Fabric Genomics is an AI-driven genomics software company headquartered in Oakland, California. The company provides bioinformatics solutions to accurately analyze whole genomes, exomes, and gene panels for clinical applications such as rare disease diagnostics.
GenDx specializes in molecular diagnostics for transplantation and personalized healthcare, providing pre- and post-transplant reagents, NGS-based typing assays, and analysis software. The company serves diagnostic laboratories, transplant centers, and researchers by offering products and technical support for HLA typing, chimerism monitoring, and related applications.
Insight Molecular Diagnostics Inc., which transitioned from its former name OncoCyte Corporation in June 2025, functions as a specialized diagnostics enterprise with operations extending across the United States and internationally. The company's core activities involve pioneering and marketing a diverse array of diagnostic solutions, including laboratory developed tests, kitted products intended solely for research, and comprehensive kitted clinical tests. Its developmental pipeline features advanced tools such as DetermaCNI, a blood-based monitoring system engineered to identify early cancer progression promptly after just one treatment cycle. Another significant offering, DetermaIO, is a gene expression assay designed to evaluate the tumor microenvironment, thereby helping to predict a patient's potential response to immunotherapies. In the critical field of organ transplantation, Insight Molecular Diagnostics provides several vital monitoring products. Both VitaGraft Kidney and VitaGraft Liver are blood-based tests that precisely measure the concentration of donor-derived cell-free DNA (dd-cfDNA) to assess the status of kidney and liver transplants, respectively. Additionally, GraftAssure represents a sophisticated dd-cfDNA test that leverages droplet digital PCR (ddPCR) technology to quantify dd-cfDNA levels by examining 48 predefined single nucleotide polymorphisms (SNPs). Beyond its product offerings, the company delivers various specialized services, including biomarker discovery, comprehensive assay design and development, support for clinical trials, and a range of general biomarker testing. Furthermore, Insight Molecular Diagnostics maintains a strategic partnership with Bio-Rad Laboratories, Inc. This collaboration focuses on the advancement and commercialization of kitted transplant products for both research use only and in vitro diagnostics applications, utilizing Bio-Rad's proprietary ddPCR instruments and reagents. Founded in 2009, the company's headquarters are situated in Nashville, Tennessee.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Chronix Biomedical, Inc. is a molecular diagnostics company headquartered in San Jose, California, that develops blood tests for applications in cancer treatment and organ transplantation.
Get CareDx, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about CareDx, Inc.? Suggest a correction · Work at CareDx, Inc.? Claim this profile
Is this your company? Add the Xcout Intel badge to your website
Free, for any company on Xcout Intel. It links visitors to this profile.
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CareDx, Inc. in Xcout Intel
- 25 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access